Who
Hans Lennart Rudolf Wigzell
Director
Company insider
Files Form 4 as: Director, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 68
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $11.0M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 8 Jun 2010
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,792 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,383 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,500 at $0.00 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $144K10,500 at $13.71 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M10,500 at $124.84 | filing |
| 8 Mar 2024filed 11 Mar 2024 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $209K15,000 at $13.90 | filing |
| 8 Mar 2024filed 11 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $391K3,155 at $123.85 | filing |
| 8 Mar 2024filed 11 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M11,745 at $123.10 | filing |
| 8 Mar 2024filed 11 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K100 at $122.39 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,679 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,846 at $0.00 | filing |
| 4 Aug 2023filed 8 Aug 2023 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 4 Aug 2023filed 8 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | $435K15,000 at $29.03 | filing |
| 4 Aug 2023filed 8 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M15,000 at $106.72 | filing |
| 6 Mar 2023filed 8 Mar 2023 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,257 at $0.00 | filing |
| 6 Mar 2023filed 8 Mar 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,523 at $0.00 | filing |
| 7 Mar 2022filed 8 Mar 2022 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,077 at $0.00 | filing |
News
Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)SRPT · dailypolitical.com · 22 Oct 2026Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8.2% – Time to Buy?SRPT · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Hans Lennart Rudolf Wigzell; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.